Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer

Video

In Partnership With:

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Many of the bladder cancer immunotherapy trials are designed to focus on recurrence of systemic disease and to look at the disease outside of the bladder. Those are the most mature trials and are leading to many of the FDA approvals.

However, we’re in a new phase where many of the new agents are being used to treat superficial disease inside the bladder. In the next 2 to 3 years, trials will be focused on determining if the systemic agents can treat bladder cancer that has not yet invaded the bladder wall.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,